Welcome to our dedicated page for VERTEX PHARMACEUTICALS / MA SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERTEX PHARMACEUTICALS / MA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERTEX PHARMACEUTICALS / MA's regulatory disclosures and financial reporting.
VRTX affiliate filed a Form 144 reporting proposed and recent sales of Common Stock. The filing lists a proposed sale tied to restricted stock vesting on 02/24/2026 for 596 shares and multiple actual sale transactions by Carmen R. Bozic between 03/27/2026 and 06/18/2026, with per‑trade share counts and gross proceeds shown.
The filings identify Fidelity Brokerage Services LLC as the broker and show the securities are listed on NASDAQ. The notice is a routine affiliate resale disclosure under Form 144.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. As EVP and Chief Medical Officer, Bozic sold 1,020 shares of Vertex Pharmaceuticals common stock at a price of $462.17 per share on June 18, 2026.
After this transaction, Bozic directly holds 15,933 shares of Vertex common stock. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan, which was entered into on November 20, 2025, indicating the trade was pre-scheduled rather than timed discretionarily.
Vertex Pharmaceuticals notice of proposed sale relates to Common stock tied to a restricted stock vesting event of 1,020 shares dated 02/17/2026. The filing also lists recent open-market dispositions by Carmen R. Bozic totaling multiple transactions between 03/27/2026 and 06/15/2026 with individual share counts and proceeds disclosed.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of common stock. On June 15, 2026, she sold 4,062 shares of Vertex common stock at $450.00 per share. After this transaction, she directly holds 16,953 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan approved by the company and entered into on November 20, 2025. This indicates the timing of the sale was set in advance as part of a structured trading program.
Filer submitted a Form 144 notice reporting a proposed sale of 4,062 shares of Common Stock on 06/15/2026. The filing lists $1,827,900.00 alongside 253,805,417 (appearing on the same cover line). The filing also records recent sales by Carmen Bozic, including 2,329 shares on 03/27/2026 and 6,988 shares on 05/12/2026.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold 1,745 shares of common stock in an open-market transaction at $450 per share. The sale on June 5, 2026 was made under a company-approved Rule 10b5-1 trading plan. After the sale, she directly holds 21,015 shares.
Carmen R. Bozic reported multiple open-market dispositions of Common Stock under a Form 144 notice. The filing lists five sales on 03/13/2026, 03/27/2026, 05/12/2026, 05/15/2026, and 05/29/2026 with reported share counts of 2,329, 2,329, 6,988, 1,354, and 1,974 respectively and the corresponding consideration amounts shown in the filing.
The notice also lists Fidelity Brokerage Services LLC as the brokerage location and records an entry for Restricted Stock Vesting dated 02/10/2026.
Vertex Pharmaceuticals executive Joy Liu reported an open-market sale of company stock. As EVP and Chief Legal Officer, she sold 828 shares of Common Stock at a price of $439.91 per share on June 1, 2026. After this transaction, she directly holds 19,959 shares of Vertex common stock. The sale was made under a pre-arranged company-approved trading plan established pursuant to Rule 10b5-1, indicating it was scheduled in advance rather than timed discretionarily.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of 1,974 shares of Common Stock at $450.00 per share. The transaction left her with 22,760 shares held directly. According to the disclosure, the sale was made under a pre-arranged Rule 10b5-1 trading plan entered into on 11/20/2025, indicating it was scheduled in advance rather than timed discretionarily.
Vertex Pharmaceuticals insider sale notice: A Form 144 submission lists proposed or recent dispositions of Common stock by Joy Liu. The excerpt shows three reported sales in the past three months: 03/02/2026 (892 shares, $442,396.32), 04/01/2026 (978 shares, $439,288.26), and 05/01/2026 (1,104 shares, $469,222.08). The filing also records an allocation of 828 shares tied to Restricted Stock Vesting dated 02/26/2025.